Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK2330811 in Healthy Japanese Participants
NCT04138043Phase 1Completed
- Sponsor
- GSK
- Start
- Dec 2019
- Primary completion
- May 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Crohn's disease and systemic sclerosis (SSc) comparing GSK2330811 450 mg with Placebo (2 arms). Primary endpoints: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs), Number of Participants With Worst Case Vital Sign Results Relative to Potential Clinical Importance (PCI) Criteria and 5 more. Started Dec 2019; status: completed.
02
Drugs
gsk2330811
03
Conditions
Crohn's diseasesystemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT04138043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04138043.